← FDA DRUG APPROVALS

FDA BLA · BLA103786

RETAVASE

Sponsor: EKR THERAP

APPLICATION
BLA103786
TYPE
BLA
ORIGINAL APPROVAL
1998-05-06
LATEST ACTION
1998-05-06
DOSAGE FORM
VIAL
MARKETING STATUS
Prescription

Products

RETAVASEPrescription
RETEPLASE 18.8MG/VIAL · VIAL

Approval history

1998-05-06Type 1 - New Molecular Entity · Original · unknownLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →